PepGen falls after US FDA puts partial hold on mid‑stage drug trial

PepGen

04/03/2026 22:01

** Shares of drug developer PepGen PEPG.O fall 17% to $5.60 in extended trading

** PEPG says the U.S. FDA has put a partial clinical hold on its mid‑stage trial of a rare muscle disease drug

** The drug, PGN‑EDODM1, is being tested for myotonic dystrophy type 1, which causes progressive muscle weakness

** Co says the health regulator's concerns relate to earlier lab and animal studies the company submitted

** PEPG says it's working with the FDA to address the questions and will submit additional info

** PEPG rose 72.7% in 2025

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))